{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:24:12Z","timestamp":1790407452818,"version":"4.1.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2011,9,20]],"date-time":"2011-09-20T00:00:00Z","timestamp":1316476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to: Describe the genetic syndromes associated with pancreas adenocarcinoma.Explain the potential role of platinum-based therapy and PARP inhibitors in BRCA-mutated pancreas adenocarcinoma.<\/jats:p>\n                  <jats:p>CME This article is available for continuing medical education credit at CME.TheOncologist.com<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>BRCA1 and BRCA2 germline mutations are associated with an elevated risk for pancreas adenocarcinoma (PAC). Other BRCA-associated cancers have been shown to have greater sensitivity to platinum and poly(ADP-ribose) polymerase (PARP) inhibitors with better clinical outcomes than in sporadic cases; however, outcomes in BRCA-associated PAC have not been reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>Patients with a known BRCA1 or BRCA2 mutation and a diagnosis of PAC were identified from the Gastrointestinal Oncology Service, Familial Pancreas Cancer Registry, and Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Fifteen patients, five male, with a BRCA1 (n = 4) or BRCA2 (n = 11) mutation and PAC and one patient with a BRCA1 mutation and acinar cell carcinoma of the pancreas were identified. Seven female patients (70%) had a prior history of breast cancer. Four patients received a PARP inhibitor alone or in combination with chemotherapy; three demonstrated an initial radiographic partial response by Response Evaluation Criteria in Solid Tumors whereas one patient had stable disease for 6 months. Six patients received platinum-based chemotherapy first line for metastatic disease; five of those patients had a radiographic partial response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>BRCA mutation\u2013associated PAC represents an underidentified, but clinically important, subgroup of patients. This is of particular relevance given the ongoing development of therapeutic agents targeting DNA repair, which may potentially offer a significant benefit to a genetically selected population. We anticipate that further study and understanding of the clinical and biologic features of BRCA-mutant PAC will aid in the identification of tissue biomarkers indicating defective tumor DNA repair pathways in sporadic PAC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2011-0185","type":"journal-article","created":{"date-parts":[[2011,9,21]],"date-time":"2011-09-21T04:48:59Z","timestamp":1316580539000},"page":"1397-1402","source":"Crossref","is-referenced-by-count":209,"title":["An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known <i>BRCA<\/i> Mutation: Clinical Descriptors, Treatment Implications, and Future Directions"],"prefix":"10.1093","volume":"16","author":[{"given":"Maeve A.","family":"Lowery","sequence":"first","affiliation":[{"name":"a Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Kelsen","sequence":"additional","affiliation":[{"name":"a Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia K.","family":"Stadler","sequence":"additional","affiliation":[{"name":"a Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"},{"name":"b Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Yu","sequence":"additional","affiliation":[{"name":"a Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena Y.","family":"Janjigian","sequence":"additional","affiliation":[{"name":"a Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmy","family":"Ludwig","sequence":"additional","affiliation":[{"name":"c Gastroenterology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"D'Adamo","sequence":"additional","affiliation":[{"name":"a Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Salo-Mullen","sequence":"additional","affiliation":[{"name":"b Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Robson","sequence":"additional","affiliation":[{"name":"b Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Allen","sequence":"additional","affiliation":[{"name":"d Hepatopancreaticobiliary Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Kurtz","sequence":"additional","affiliation":[{"name":"c Gastroenterology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O'Reilly","sequence":"additional","affiliation":[{"name":"a Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,9,20]]},"reference":[{"key":"2021122304021433300_B1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"2021122304021433300_B2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jnci\/95.3.214","article-title":"BRCA2 germline mutations in familial pancreatic carcinoma","volume":"95","author":"Hahn","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2021122304021433300_B3","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers. J. Natl","volume":"91","author":"The Breast Cancer Linkage Consortium","year":"1999","journal-title":"Cancer Inst"},{"key":"2021122304021433300_B4","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","article-title":"Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program","volume":"94","author":"Brose","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122304021433300_B5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ygyno.2010.12.354","article-title":"Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations","volume":"121","author":"Lacour","year":"2011","journal-title":"Gynecol Oncol"},{"key":"2021122304021433300_B6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2008.18.5546","article-title":"BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma","volume":"27","author":"Ferrone","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122304021433300_B7","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122304021433300_B8","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"15 suppl","key":"2021122304021433300_B9","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1200\/jco.2010.28.15_suppl.4152","article-title":"Clinical outcomes in pancreatic adenocarcinoma (PAC) in breast cancer (BC) survivors","volume":"28","author":"Lowery","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122304021433300_B10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2009.10.021","article-title":"Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective","volume":"46","author":"Sandhu","year":"2010","journal-title":"Eur J Cancer"},{"key":"2021122304021433300_B11","doi-asserted-by":"crossref","first-page":"934","DOI":"10.4161\/cbt.4.9.2141","article-title":"BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly(ADP-ribose) polymerase: An issue of potency","volume":"4","author":"McCabe","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"2021122304021433300_B12","first-page":"305","article-title":"Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation","volume":"9","author":"Chalasani","year":"2008","journal-title":"JOP"},{"key":"2021122304021433300_B13","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0185","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/10\/1397\/41857078\/oncolo_16_10_1397.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/10\/1397\/41857078\/oncolo_16_10_1397.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T09:47:27Z","timestamp":1640252847000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/10\/1397\/6401820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,20]]},"references-count":13,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2011,9,20]]},"published-print":{"date-parts":[[2011,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0185","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,10,1]]},"published":{"date-parts":[[2011,9,20]]}}}